What is the recommended schedule and protocol for Hepatitis A (Hep A) vaccination?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hepatitis A Vaccination Schedule and Protocol

The recommended Hepatitis A vaccination schedule consists of a 2-dose series, with the first dose administered at 12-23 months of age and the second dose given 6-12 months later for Havrix or 6-18 months later for Vaqta. 1

Standard Vaccination Schedule by Age Group

Children (1-18 years)

  • First dose at 12-23 months of age as part of routine childhood immunization 1
  • Second dose:
    • Havrix (720 ELU, 0.5 mL): 6-12 months after first dose 1
    • Vaqta (25 U, 0.5 mL): 6-18 months after first dose 1

Adults (≥19 years)

  • Two-dose series:
    • Havrix (1440 ELU, 1.0 mL): Initial dose followed by second dose 6-12 months later 1
    • Vaqta (50 U, 1.0 mL): Initial dose followed by second dose 6-18 months later 1
  • Twinrix (combined Hepatitis A and B vaccine): 3-dose series at 0,1, and 6 months for adults ≥18 years 1

Special Populations and Considerations

Immunocompromised Persons and Those with Chronic Liver Disease

  • Should receive both Hepatitis A vaccine and immune globulin (IG) simultaneously at different anatomic sites when exposed to HAV within the past 14 days 1
  • For preexposure protection, should receive one dose of vaccine plus IG (0.1-0.2 mL/kg) based on provider's risk assessment 1
  • Immunocompromising conditions are not a contraindication to receiving hepatitis A vaccine 1

International Travelers

  • Infants 6-11 months: One dose of HepA vaccine before departure (this dose doesn't count toward routine 2-dose series) 1
  • Children and adults 12 months-40 years: Single dose of HepA vaccine as soon as travel is considered 1
  • Adults >40 years, immunocompromised persons, and those with chronic liver disease traveling to high/intermediate endemic areas with <2 weeks before departure: Initial dose of HepA vaccine plus IG (0.1-0.2 mL/kg) at separate injection sites 1
  • For travel duration >2 months: IG dose should be repeated every 2 months if continued protection is needed 1

Postexposure Prophylaxis (PEP)

  • Should be administered within 14 days of exposure 1
  • Children 12 months-40 years: One dose of HepA vaccine 1
  • Adults >40 years: One dose of HepA vaccine; IG (0.1 mL/kg) may also be given based on provider's risk assessment 1
  • Immunocompromised persons or those with chronic liver disease: Both HepA vaccine and IG (0.1 mL/kg) simultaneously at different anatomic sites 1

Administration Guidelines

  • Administer intramuscularly with appropriate needle length based on age and size 1
  • Shake vaccine well before administration; properly mixed vaccine appears as a slightly opaque, white-colored suspension 1
  • If vaccination schedule is interrupted, only the required doses need to be administered (no need to restart series) 1
  • Different brands of hepatitis A vaccines are interchangeable for completing the series 1

Storage Requirements

  • Store between 2°C and 8°C (36°F and 46°F) 1
  • Do not freeze, as freezing destroys vaccine potency 1

Important Clinical Considerations

  • Seroconversion rates exceed 95% in healthy children and adults after a single dose 2
  • Antibody persistence is excellent for at least 12 months after one dose, allowing flexibility in timing of the booster dose 3, 4
  • For last-minute travelers, the vaccine can be administered at any time before departure as it provides significant protection even with late administration 5
  • No serologic testing is recommended before or after vaccination in the general population 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hepatitis A vaccine: ready for prime time.

Obstetrics and gynecology, 1998

Research

Hepatitis A vaccine in the last-minute traveler.

The American journal of medicine, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.